Adjuvant Therapeutics Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Adjuvant Therapeutics General Information


Developer of a cancer treatment technology designed to improve cancer treatment. The company's technology offers a system called OncO2, that increase oxygen concentrations in tumors, enabling physicians to improve the effectiveness of radiotherapy for cancer treatment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Other Devices and Supplies
Corporate Office
  • 1344 Summer Street
  • Suite 311.1
  • Halifax, Nova Scotia B3H 0A8
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adjuvant Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Feb-2018 Completed Out of Business
1. Accelerator/Incubator Completed Startup
To view Adjuvant Therapeutics’s complete valuation and funding history, request access »

Adjuvant Therapeutics FAQs

  • Where is Adjuvant Therapeutics headquartered?

    Adjuvant Therapeutics is headquartered in Halifax, Canada.

  • What industry is Adjuvant Therapeutics in?

    Adjuvant Therapeutics’s primary industry is Other Healthcare Technology Systems.

  • Is Adjuvant Therapeutics a private or public company?

    Adjuvant Therapeutics is a Private company.

  • What is Adjuvant Therapeutics’s current revenue?

    The current revenue for Adjuvant Therapeutics is 000000.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »